Reference entry · PTH(1-34) fragment
Teriparatide
Also known as: PTH(1-34) · Forteo · recombinant human parathyroid hormone
- Class
- PTH(1-34) fragment
- Size
- 34 amino acids
- Primary targets (literature)
- PTH1 receptor (anabolic bone formation with intermittent exposure)
- Regulatory context
- FDA-approved (Forteo and biosimilars). RUO catalog teriparatide is not pharmaceutical Forteo without verified sourcing.
Overview
Teriparatide is FDA-approved PTH(1-34) for high-risk osteoporosis. Fracture Prevention Trial data established vertebral and nonvertebral fracture reduction — a formal clinical tier distinct from catalog repair peptides.
Mechanism in research literature
Intermittent PTH1 receptor activation stimulates bone formation more than resorption, increasing BMD and trabecular architecture in trial-defined populations.
Common research focus areas
- Fracture Prevention Trial and alendronate comparison
- Glucocorticoid-induced osteoporosis indications
- Osteosarcoma label history and post-marketing surveillance
- MS identity vs. abaloparatide and unrelated repair peptides
Full literature roundup
Read the cited research summary
Recombinant PTH(1-34) — the first widely approved bone anabolic peptide. Fracture trial data, intermittent PTH biology, and why catalog material differs from Forteo.
Teriparatide research roundup · 4 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.